ReNeuron Group PLC (RENE)

Back to homepage

Company Description

ReNeuron Group PLC was incorporated in England on June 7, 2005. The Company is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. The Company's main therapeutic candidate is ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. Its three principal stem cell therapy programmes are ReN001 for stroke disability, ReN009 stem cell therapy for critical limb ischaemia, and ReN003 stem cell therapy for retinitis pigmentosa. The Company operates under the sole business segment of development of cell-based therapies...